EGFR and cancer: Ultimately, the issue of cancer drug discovery is two-fold in that while with the help of next-generation sequencing, large cohorts of patients have been identified with novel targeted therapeutic options such as NSCLC EGFR-mutated patients or BRCA-2 positive breast cancer, there were also numerous cohorts of patients discovered with genomic alterations that have no clinically proven drug options such as TP53, ARID1A or PIK3CA [24].